European markets have shown tentative optimism recently, buoyed by the potential for a new EU-U.S. trade deal and steady economic performance across the eurozone. In this context, penny stocks—though an old term—remain relevant as they represent smaller or newer companies with potential growth opportunities. These stocks can offer affordability and growth potential, particularly when backed by strong financials, making them an intriguing option for investors seeking hidden value in quality companies.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Lucisano Media Group (BIT:LMG) | €0.95 | €14.11M | ✅ 3 ⚠️ 4 View Analysis > |
| Maps (BIT:MAPS) | €3.45 | €45.82M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| IAMBA Arad (BVB:FERO) | RON0.494 | RON16.71M | ✅ 2 ⚠️ 4 View Analysis > |
| Cellularline (BIT:CELL) | €2.93 | €61.8M | ✅ 4 ⚠️ 2 View Analysis > |
| Libertas 7 (BME:LIB) | €2.30 | €49.01M | ✅ 4 ⚠️ 4 View Analysis > |
| Bredband2 i Skandinavien (OM:BRE2) | SEK3.255 | SEK3.12B | ✅ 4 ⚠️ 2 View Analysis > |
| Euroland Société anonyme (ENXTPA:ALERO) | €3.26 | €10.34M | ✅ 2 ⚠️ 5 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.145 | €296.15M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.97 | €32.71M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 335 stocks from our European Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Aelis Farma (ENXTPA:AELIS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Aelis Farma SA is a clinical-stage biopharmaceutical company in France that discovers and develops drug candidates for central nervous system disorders, with a market cap of €10.87 million.
Operations: The company generates €5.56 million in revenue from the research and development of pharmaceutical products.
Market Cap: €10.87M
Aelis Farma, a clinical-stage biopharmaceutical company in France, is navigating the penny stock landscape with a market cap of €10.87 million and generating €5.56 million in revenue from R&D activities. The management and board are experienced, with average tenures of 3.5 and 4 years respectively. While currently unprofitable with increasing losses over five years, the company has reduced its debt-to-equity ratio significantly over this period and maintains more cash than total debt. Despite high share price volatility, Aelis Farma trades at good value compared to industry peers and has not seen meaningful shareholder dilution recently.
- Jump into the full analysis health report here for a deeper understanding of Aelis Farma.
- Review our growth performance report to gain insights into Aelis Farma's future.
Reworld Media Société Anonyme (ENXTPA:ALREW)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Reworld Media Société Anonyme operates in the thematic media sector in France and has a market cap of €89.34 million.
Operations: Reworld Media's revenue is divided into two segments: B to B, generating €308.6 million, and B to C, contributing €226.1 million.
Market Cap: €89.34M
Reworld Media Société Anonyme, with a market cap of €89.34 million, operates in the thematic media sector and presents a mixed picture for penny stock investors. Despite high-quality past earnings and seasoned management, the company faces challenges such as negative earnings growth over the past year and declining profit margins. The company's debt is well-covered by operating cash flow, but it holds a high net debt to equity ratio of 43.5%. While trading at good value compared to peers and industry standards, short-term liabilities exceed short-term assets, indicating potential liquidity concerns despite stable weekly volatility.
- Click to explore a detailed breakdown of our findings in Reworld Media Société Anonyme's financial health report.
- Gain insights into Reworld Media Société Anonyme's future direction by reviewing our growth report.
NEXT Biometrics Group (OB:NEXT)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: NEXT Biometrics Group ASA, with a market cap of NOK513.59 million, operates in Asia, Europe, Africa, and North America providing fingerprint sensor technology through its subsidiaries.
Operations: The company generates revenue primarily from its Fingerprint Sensor Technology segment, amounting to NOK65.66 million.
Market Cap: NOK513.59M
NEXT Biometrics Group ASA, with a market cap of NOK513.59 million, presents a nuanced opportunity for penny stock investors. The company is debt-free and has extended key partnerships, such as those with XM Holder and ACPL, potentially enhancing revenue streams through significant orders valued up to NOK 107 million. Despite these promising developments, NEXT remains unprofitable with less than a year of cash runway based on current free cash flow. Recent sales have declined to NOK 6.89 million from NOK 12.8 million the previous year, highlighting ongoing financial challenges amidst its strategic initiatives in fingerprint sensor technology markets globally.
- Unlock comprehensive insights into our analysis of NEXT Biometrics Group stock in this financial health report.
- Gain insights into NEXT Biometrics Group's past trends and performance with our report on the company's historical track record.
Key Takeaways
- Embark on your investment journey to our 335 European Penny Stocks selection here.
- Interested In Other Possibilities? The end of cancer? These 25 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Reworld Media Société Anonyme might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com